BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 34323652)

  • 21. Identification of a Seven-lncRNA Immune Risk Signature and Construction of a Predictive Nomogram for Lung Adenocarcinoma.
    Jin D; Song Y; Chen Y; Zhang P
    Biomed Res Int; 2020; 2020():7929132. PubMed ID: 32596372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and validation of a novel epigenetic-related prognostic signature and candidate drugs for patients with lung adenocarcinoma.
    Wang Z; Embaye KS; Yang Q; Qin L; Zhang C; Liu L; Zhan X; Zhang F; Wang X; Qin S
    Aging (Albany NY); 2021 Jul; 13(14):18701-18717. PubMed ID: 34285141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of metabolism-related gene signature in lung adenocarcinoma.
    Wang N; Wang H
    Medicine (Baltimore); 2023 Nov; 102(47):e36267. PubMed ID: 38013279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of an immune-related gene pairs signature for predicting clinical outcome in lung adenocarcinoma.
    Wu C; Hu Q; Ma D
    Sci Rep; 2021 Feb; 11(1):3611. PubMed ID: 33574499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel ferroptosis-related genes model for prognosis prediction of lung adenocarcinoma.
    Li F; Ge D; Sun SL
    BMC Pulm Med; 2021 Jul; 21(1):229. PubMed ID: 34256754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma.
    Zhai Y; Zhao B; Wang Y; Li L; Li J; Li X; Chang L; Chen Q; Liao Z
    BMC Cancer; 2021 Mar; 21(1):213. PubMed ID: 33648465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishment and validation of an eight-gene metabolic-related prognostic signature model for lung adenocarcinoma.
    Ma W; Liang J; Liu J; Tian D; Chen Z
    Aging (Albany NY); 2021 Feb; 13(6):8688-8705. PubMed ID: 33619235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictions of the dysregulated competing endogenous RNA signature involved in the progression of human lung adenocarcinoma.
    Yang D; He Y; Wu B; Liu R; Wang N; Wang T; Luo Y; Li Y; Liu Y
    Cancer Biomark; 2020; 29(3):399-416. PubMed ID: 32741804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deciphering N
    Zhu J; Wang M; Hu D
    Biomed Res Int; 2020; 2020():2514230. PubMed ID: 32258108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification and Validation of a Proliferation-Associated Score Model Predicting Survival in Lung Adenocarcinomas.
    Bian Y; Sui Q; Bi G; Zheng Y; Zhao M; Yao G; Xue L; Zhang Y; Fan H
    Dis Markers; 2021; 2021():3219594. PubMed ID: 34721732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploring exosome data to identify prognostic gene signatures for lung adenocarcinoma.
    Li J; Gao X; Tian S; Tang M; Liu W
    Future Oncol; 2021 Dec; 17(34):4745-4756. PubMed ID: 34658257
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a four-gene panel predicting overall survival for lung adenocarcinoma.
    Li C; Long Q; Zhang D; Li J; Zhang X
    BMC Cancer; 2020 Dec; 20(1):1198. PubMed ID: 33287749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification and analysis of prognostic immune cell homeostasis characteristics in lung adenocarcinoma.
    Sun Y; Ma Q; Chen Y; Liao D; Kong F
    Clin Respir J; 2024 May; 18(5):e13755. PubMed ID: 38757752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eight-gene signature predicts recurrence in lung adenocarcinoma.
    Zhang Y; Fan Q; Guo Y; Zhu K
    Cancer Biomark; 2020; 28(4):447-457. PubMed ID: 32508318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel transcriptomic signature associated with lymphovascular invasion predicts clinical outcomes, tumor microenvironment, and therapeutic response in lung adenocarcinoma.
    Huang X; Feng Y; Li Y; Ding H; Huang X; Chen C; Yu Z; Zhang J; Xu X; Ma D; Yu S; Chen C
    Int Immunopharmacol; 2024 Jan; 127():111286. PubMed ID: 38064818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune-related eight-lncRNA signature for improving prognosis prediction of lung adenocarcinoma.
    Chen Y; Zhang X; Li J; Zhou M
    J Clin Lab Anal; 2021 Nov; 35(11):e24018. PubMed ID: 34550610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. N-6 methylation-related lncRNA is potential signature in lung adenocarcinoma and influences tumor microenvironment.
    Zheng J; Zhao Z; Wan J; Guo M; Wang Y; Yang Z; Li Z; Ming L; Qin Z
    J Clin Lab Anal; 2021 Nov; 35(11):e23951. PubMed ID: 34558724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of genomic and transcriptomic variations as prognostic signature for lung adenocarcinoma.
    Zengin T; Önal-Süzek T
    BMC Bioinformatics; 2020 Sep; 21(Suppl 14):368. PubMed ID: 32998690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.